CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Name: CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Published: 2018
License: Public Domain

Calithera Biosciences, Inc · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

advanced renal cell carcinoma, metastatic renal cell carcinoma, tumor metabolism, rcc, glutaminase inhibitor, cb-839, cantata, tki, tyrosine kinase inhibitor, cabozantinib, cabometyx, cometriq

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 1031645
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.